ARTICLE | Clinical News
Relenza zanamivir regulatory update
May 8, 2006 7:00 AM UTC
The partners received marketing approval in Australia to expand the label for Relenza zanamivir to include prophylaxis against influenza in children 5 years of age and older. The neuraminidase inhibi...